Low PKCα expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcome

Oncotarget

Volumn 5, Issue 14, 2014, Pages 5234-5245

  Milani, Gloria ^a   Rebora, Paola ^b   Accordi, Benedetta ^a   Galla, Luisa ^a   Bresolin, Silvia ^a   Cazzaniga, Gianni ^c   Buldini, Barbara ^a   Mura, Rossella ^d   Ladogana, Saverio ^e   Giraldi, Eugenia ^f   Conter, Valentino ^c   Kronnie, Geertruy Te ^a   Valsecchi, Maria Grazia ^b   Basso, Giuseppe ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

^d Osp Regionale per le Microcitemie   (Italy)

^e Oncoematologia Pediatrica Ospedale 'Casa Solievo della Sofferenza'   (Italy)

^f PAPA GIOVANNI XXIII HOSPITAL   (Italy)

Author keywords

Childhood T cell Acute Lymphoblastic Leukemia; Low PKC expression; T ALL prognostic marker

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; PROTEIN KINASE C ALPHA; PRKCA PROTEIN, HUMAN; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CHILD; CHILDHOOD LEUKEMIA; DOWN REGULATION; EVENT FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PKC ALPHA GENE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PROTEIN EXPRESSION; PROTEOMICS; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME; BIOSYNTHESIS; ENZYMOLOGY; GENETICS; INFANT; METABOLISM; PROGNOSIS; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; NEOPLASM, RESIDUAL; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROTEIN KINASE C-ALPHA; RISK FACTORS; RNA, MESSENGER; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84906241260     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2062     Document Type: Article

References (29)

1. Pui C-H, Relling M V, Downing JR. Acute lymphoblastic leukemia. N. Engl. J. Med. 2004;350(15):1535-48.
2. Kraszewska MD, Dawidowska M, Szczepański T, Witt M. T-cell acute lymphoblastic leukaemia: recent molecular biology findings. Br. J. Haematol. 2012;156(3):303-15.
3. Ferrando AA, Look AT. Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia. Semin. Hematol. 2000;37(4):381-95.
4. Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, Behm FG, Pui CH, Downing JR, Gilliland DG, Lander ES, Golub TR, Look AT. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1(1):75-87.
5. Pui C-H, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030-43.
6. Pui C-H, Mullighan CG, Evans WE, Relling M V. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012;120(6):1165-74.
7. Pui C-H, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J. Clin. Oncol. 2011;29(5):551-65.
8. Van Vlierberghe P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. J. Clin. Invest. 2012;122(10):3398-406.
9. Pui C-H, Evans WE. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 2006;354(2):166-78.
10. Schrappe M, Valsecchi MG, Bartram CR, Schrauder A, Panzer-Grüümayer R, Möricke A, Parasole R, Zimmermann M, Dworzak M, Buldini B, Reiter A, Basso G, Klingebiel T, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011;118(8):2077-84.
11. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, Cheng C, Su X, Rubnitz JE, Basso G, Biondi A, Pui CH, Downing JR, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10(2):147-56.
12. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50.
13. Herold R, von Stackelberg A, Hartmann R, Eisenreich B, Henze G. Acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group (ALL-REZ BFM) experience: early treatment intensity makes the difference. J. Clin. Oncol. 2004;22(3):569-70; author reply 570-1.
14. Hurley JH, Misra S. Signaling and subcellular targeting by membrane-binding domains. Annu. Rev. Biophys. Biomol. Struct. 2000;29:49-79.
15. Way KJ, Chou E, King GL. Identification of PKC-isoform-specific biological actions using pharmacological approaches. Trends Pharmacol. Sci. 2000;21(5):181-7.
16. Detjen KM, Brembeck FH, Welzel M, Kaiser A, Haller H, Wiedenmann B, Rosewicz S. Activation of protein kinase Calpha inhibits growth of pancreatic cancer cells via p21(cip)-mediated G(1) arrest. J. Cell Sci. 2000;113 ( Pt 1:3025-35.
17. Pysz MA, Leontieva O V, Bateman NW, Uronis JM, Curry KJ, Threadgill DW, Janssen KP, Robine S, Velcich A, Augenlicht LH, Black AR, Black JD. PKCalpha tumor suppression in the intestine is associated with transcriptional and translational inhibition of cyclin D1. Exp. Cell Res. 2009;315(8):1415-28.
18. Nakagawa R, Soh JW, Michie AM. Subversion of protein kinase C alpha signaling in hematopoietic progenitor cells results in the generation of a B-cell chronic lymphocytic leukemia-like population in vivo. Cancer Res. 2006;66(1):527-34.
19. Lin K-Y, Fang C-L, Uen Y-H, Chang CC, Lou HY, Hsieh CR, Tiong C, Pan S, Chen SH. Overexpression of protein kinase Calpha mRNA maybe an independent prognostic marker for gastric carcinoma. J. Surg. Oncol. 2008;97(6):538-43.
20. Lønne GK, Cornmark L, Zahirovic IO, Landberg G, Jirström K, Larsson C. PKCalpha expression is a marker for breast cancer aggressiveness. Mol. Cancer. 2010;9:76.
21. Tsai JH, Hsieh YS, Kuo SJ, Chen ST, Yu SY, Huang CY, Chang AC, Wang YW, Tsai MT, Liu JY. Alteration in the expression of protein kinase C isoforms in human hepatocellular carcinoma. Cancer Lett. 2000;161(2):171-5.
22. Wu T-T, Hsieh Y-H, Wu C-C, Hsieh Y-S, Huang C-Y, Liu J-Y. Overexpression of protein kinase C alpha mRNA in human hepatocellular carcinoma: a potential marker of disease prognosis. Clin. Chim. Acta. 2007;382(1-2):54-8.
23. Franz MG, Norman JG, Fabri PJ, Gower WR. Differentiation of pancreatic ductal carcinoma cells associated with selective expression of protein kinase C isoforms. Ann. Surg. Oncol. 1996;3(6):564-9.
24. Lahn M, Paterson BM, Sundell K, Ma D. The role of protein kinase C-alpha (PKC-alpha) in malignancies of the gastrointestinal tract. Eur. J. Cancer. 2004;40(1):10-20.
25. Basso G, Buldini B, De Zen L, Orfao A. New methodologic approaches for immunophenotyping acute leukemias. Haematologica. 2001;86(7):675-92.
26. Accordi B, Espina V, Giordan M, VanMeter A, Milani G, Galla L, Ruzzene M, Sciro M, Trentin L, De Maria R, te Kronnie G, Petricoin E, Liotta L, et al. Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL. PLoS One. 2010;5(10):e13552.
27. Segal E, Friedman N, Koller D, Regev A. A module map showing conditional activity of expression modules in cancer. Nat Genet. 2004; 36(10):1090-8.
28. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32-5.
29. Antolini L, Valsecchi MG. Performance of binary markers for censored failure time outcome: nonparametric approach based on proportions. Stat. Med. 2012;31(11-12):1113-28.